SCHEMBL6167631

SCHEMBL6167631

O=C(c1cc(-c2ccc(OCCCBr)cc2F)nc2ccccc12)N1CCC[C@@H]1CO

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HCRTR1 O43613 3/20 0.47
HCRTR2 O43614 3/20 0.47
POLB P06746 2/20 0.42
SPHK2 Q9NRA0 1/20 0.42
HSP90AA1 P07900 1/20 0.41
RAB9A P51151 3/20 0.41
NPC1 O15118 2/20 0.41
KDM4E B2RXH2 3/20 0.40
LMNA P02545 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
ALDH1A1 P00352 1/20 0.40
MAPK1 P28482 1/20 0.40
ADAM17 P78536 1/20 0.40
PDK2 Q15119 2/20 0.40
TRPV1 Q8NER1 2/20 0.40
TP53 P04637 1/20 0.40
DHODH Q02127 1/20 0.39
NTRK1 P04629 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6164137 1.00 HCRTR1 (0.47) HCRTR1HCRTR2POLBSPHK2HSP90AA1
SCHEMBL6165032 1.00 HCRTR1 (0.47) HCRTR1HCRTR2POLBSPHK2HSP90AA1
SCHEMBL6164654 0.90 RAB9A (0.53) HCRTR1HCRTR2POLBSPHK2HSP90AA1
SCHEMBL6163166 0.90 RAB9A (0.53) HCRTR1HCRTR2POLBSPHK2HSP90AA1
SCHEMBL6162969 0.90 RAB9A (0.53) HCRTR1HCRTR2POLBSPHK2HSP90AA1
SCHEMBL6163699 0.88 POLB (0.55) HCRTR1HCRTR2POLBHSP90AA1RAB9A
SCHEMBL6165715 0.88 POLB (0.55) HCRTR1HCRTR2POLBHSP90AA1RAB9A
SCHEMBL6163817 0.88 POLB (0.55) HCRTR1HCRTR2POLBHSP90AA1RAB9A
SCHEMBL6165793 0.85 HCRTR1 (0.51) HCRTR1HCRTR2POLBRAB9AKDM4E
SCHEMBL6163609 0.85 HCRTR1 (0.51) HCRTR1HCRTR2POLBRAB9AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1337523-B1 2,4-SUBSTITUTED PYRIDINE DERIVATIVES NEUROGEN CORP (US) 2005-10-19 EP claimed
US-20040048867-A1 2,4-Substituted pyridine derivatives NEUROGEN CORPORATION 2004-03-11 US claimed
US-6559163-B2 Agonists, antagonists or inverse agonists for GABAA brain receptors; useful in diagnosis and treatment of anxiety, depression NEUROGEN CORPORATION 2003-05-06 US claimed
US-20020161008-A1 2,4-Substituted pyridine derivatives NEUROGEN CORPORATION 2002-10-31 US claimed
US-6559163-B2 Agonists, antagonists or inverse agonists for GABAA brain receptors; useful in diagnosis and treatment of anxiety, depression NEUROGEN CORPORATION 2003-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020161008-A1 2,4-Substituted pyridine derivatives GABARAP, GABRB1, GABARAPL1 HCRTR1 81/4885HCRTR2 88/4885POLB 1324/4885
US-20040048867-A1 2,4-Substituted pyridine derivatives GABARAP, GABRB1, GABARAPL1 HCRTR1 81/4885HCRTR2 88/4885POLB 1324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.